Stephen John Briddon

Dr. Stephen John Briddon

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1998 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JGJonathan M. Gibbins
Jonathan M. Gibbins
SBStephen John Briddon
Stephen John Briddon
ASAdam Shutes
Adam Shutes
MVMartine J. van Vugt
Martine J. van Vugt
JWJan G.J. van de Winkel
Jan G.J. van de Winkel
SWStephen P. Watson
Stephen P. Watson
There is extensive evidence to show that phosphatidylinositol 3-kinase plays an important role in signaling by the immune family of receptors, which has recently been extended to include the platelet collagen receptor, glycoprotein VI. In this report we present two potential mechanisms for the regulation of this enzyme on stimulation of platelets by collagen. We show that on stimulation with collagen, the regulatory subunit of phosphatidylinositol 3-kinase associates with the tyrosine-phosphorylated form of the adapter protein linker for activator of T Cells (LAT) and the tyrosine-phosphorylated immunoreceptor tyrosine-based activation motif of the Fc receptor gamma-chain (a component of the collagen receptor complex that includes glycoprotein VI). The associations of the Fc receptor gamma-chain and LAT with p85 are rapid and supported by the Src-homology 2 domains of the regulatory subunit. We did not obtain evidence to support previous observations that the regulatory subunit of phosphatidylinositol 3-kinase is regulated through association with the tyrosine kinase Syk. The present results provide a molecular basis for the regulation of the p85/110 form of phosphatidylinositol 3-kinase by GPVI, the collagen receptor that underlies activation.

16 March 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
SBStephen John Briddon
Stephen John Briddon
RMR. J. Middleton
R. J. Middleton
YCY. Cordeaux
Y. Cordeaux
FFF. M. Flavin
F. M. Flavin
JWJ. A. Weinstein
J. A. Weinstein
SHStephen Hill
Stephen Hill
The A 1 -adenosine receptor (A 1 -AR) is a G protein-coupled receptor that mediates many of the physiological effects of adenosine in the brain, heart, kidney, and adipocytes. Currently, ligand interactions with the A 1 -AR can be quantified on large cell populations only by using radioligand binding. To increase the resolution of these measurements, we have designed and characterized a previously undescribed fluorescent antagonist for the A 1 -AR, XAC-BY630, based on xanthine amine congener (XAC). This compound has been used to quantify ligand-receptor binding at a single cell level using fluorescence correlation spectroscopy (FCS). XAC-BY630 was a competitive antagonist of A 1 -AR-mediated inhibition of cAMP accumulation [log 10 of the affinity constant (pK b ) = 6.7)] and stimulation of inositol phosphate accumulation (pK b = 6.5). Specific binding of XAC-BY630 to cell surface A 1 -AR could also be visualized in living Chinese hamster ovary (CHO)-A1 cells by using confocal microscopy. FCS analysis of XAC-BY630 binding to the membrane of CHO-A1 cells revealed three components with diffusion times (τ D ) of 62 μs (τ D 1 , free ligand), 17 ms (τ D 2 , A 1 -AR-ligand), and 320 ms (τ D 3 ). Confirmation that τ D 2 resulted from diffusion of ligand-receptor complexes came from the similar diffusion time observed for the fluorescent A 1 -AR-Topaz fusion protein (15 ms). Quantification of τ D 2 showed that the number of receptor-ligand complexes increased with increasing free ligand concentration and was decreased by the selective A 1 -AR antagonist, 8-cyclopentyl-1,3-dipropylxanthine. The combination of FCS with XAC-BY630 will be a powerful tool for the characterization of ligand-A 1 -AR interactions in single living cells in health and disease.

1 December 2007 in Trends in Pharmacological Sciences
Verified
Journal Article
Open access
PDF file
SBStephen John Briddon
Stephen John Briddon
SHStephen Hill
Stephen Hill
Recent years have revealed a high degree of structural organisation in the way in which cell-surface receptors and their associated signalling complexes interact at a molecular level. Fluorescence-based techniques have been at the forefront of methodologies used to investigate this organisation and dissect the pharmacology of drug–receptor interactions at the single-cell level. One such technique, fluorescence correlation spectroscopy (FCS), in conjunction with a fluorescent ligand or receptor, is capable of providing quantitative information about the number of receptors and their mobilities within small areas of the cell membrane that approach the size of some signalling domains. This article describes the use of FCS to perform subcellular quantitative pharmacology, with particular reference to G-protein-coupled receptors (GPCRs). In conjunction with other forms of fluctuation analysis, such as two-colour cross-correlation FCS and molecular brightness analysis, FCS provides the first opportunity to investigate the domain-specific nature of GPCR pharmacology.

1 September 2012 in Chemistry & Biology
Verified
Journal Article
Open access
LSLeigh A. Stoddart
Leigh A. Stoddart
AVAndrea J. Vernall
Andrea J. Vernall
JDJessica L. Denman
Jessica L. Denman
SBStephen John Briddon
Stephen John Briddon
BKBarrie Kellam
Barrie Kellam
SHStephen Hill
Stephen Hill
G protein-coupled receptors (GPCRs) comprise the largest family of transmembrane proteins. For GPCR drug discovery, it is important that ligand affinity is determined in the correct cellular environment and preferably using an unmodified receptor. We developed a live cell high-content screening assay that uses a fluorescent antagonist, CA200645, to determine binding affinity constants of competing ligands at human adenosine-A(1) and -A(3) receptors. This method was validated as a tool to screen a library of low molecular weight fragments, and identified a hit with submicromolar binding affinity (K(D)). This fragment was structurally unrelated to substructures of known adenosine receptor antagonists and was optimized to show selectivity for the adenosine-A(3) receptor. This technology represents a significant advance that will allow the determination of ligand and fragment affinities at receptors in their native membrane environment.

26 December 2019 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
MSMark Soave
Mark Soave
SBStephen John Briddon
Stephen John Briddon
SHStephen Hill
Stephen Hill
LSLeigh A. Stoddart
Leigh A. Stoddart
In recent years, several novel aspects of GPCR pharmacology have been described, which are thought to play a role in determining the in vivo efficacy of a compound. Fluorescent ligands have been used to study many of these, which have also required the development of new experimental approaches. Fluorescent ligands offer the potential to use the same fluorescent probe to perform a broad range of experiments, from single‐molecule microscopy to in vivo BRET. This review provides an overview of the in vitro use of fluorescent ligands in further understanding emerging pharmacological paradigms within the GPCR field, including ligand‐binding kinetics, allosterism and intracellular signalling, along with the use of fluorescent ligands to study physiologically relevant therapeutic agents.

23 February 2010 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
JBJillian G Baker
Jillian G Baker
RMRichard Middleton
Richard Middleton
LALuke Adams
Luke Adams
LMLauren T May
Lauren T May
SBStephen John Briddon
Stephen John Briddon
SHStephen Hill
Stephen Hill
Background and purpose:  The introduction of fluorescence‐based techniques, and in particular the development of fluorescent ligands, has allowed the study of G protein‐coupled receptor pharmacology at the single cell and single molecule level. This study evaluated how the physicochemical nature of the linker and the fluorophore affected the pharmacological properties of fluorescent agonists and antagonists.Experimental approach:  Chinese hamster ovary cells stably expressing the human adenosine A1 receptor and a cyclic 3′,5′ adenosine monophosphate response element‐secreted placental alkaline phosphatase (CRE‐SPAP) reporter gene, together with whole cell [3H]‐8‐cyclopentyl‐1,3‐dipropylxanthine (DPCPX) radioligand binding, were used to evaluate the pharmacological properties of a range of fluorescent ligands based on the antagonist xanthine amine congener (XAC) and the agonist 5′ (N‐ethylcarboxamido) adenosine (NECA).Key results:  Derivatives of NECA and XAC with different fluorophores, but equivalent linker length, showed significant differences in their binding properties to the adenosine A1 receptor. The BODIPY 630/650 derivatives had the highest affinity. Linker length also affected the pharmacological properties, depending on the fluorophore used. Particularly in fluorescent agonists, higher agonist potency could be achieved with large or small linkers for dansyl and BODIPY 630/650 derivatives, respectively.Conclusions and implications:  The pharmacology of a fluorescent ligand was critically influenced by both the fluorophore and the associated linker. Furthermore, our data strongly suggest that the physicochemical properties of the fluorophore/linker pairing determine where in the environment of the target receptor the fluorophore is placed, and this, together with the environmental sensitivity of the resulting fluorescence, may finally decide its utility as a fluorescent probe.This article is part of a themed section on Imaging in Pharmacology. To view the editorial for this themed section visit http://dx.doi.org/10.1111/j.1476‐5381.2010.00685.x